Article (Scientific journals)
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
Appel, Gerald B; Contreras, Gabriel; Dooley, Mary Anne et al.
2009In Clinical Journal of the American Society of Nephrology, 20 (5), p. 1103-1112
Peer Reviewed verified by ORBi
 

Files


Full Text
Malaise_2009_JAmSocNephrol_1103-1112.pdf
Publisher postprint (156.38 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Immunosuppressive Agents; mycophenolate mofetil; Mycophenolic Acid; Cyclophosphamide; Lupus Nephritis; Glomerular Filtration Rate
Abstract :
[en] Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, controlled trial. Here, we report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a multinational, two-phase (induction and maintenance) study. We randomly assigned 370 patients with classes III through V lupus nephritis to open-label MMF (target dosage 3 g/d) or IVC (0.5 to 1.0 g/m(2) in monthly pulses) in a 24-wk induction study. Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d. The primary end point was a prespecified decrease in urine protein/creatinine ratio and stabilization or improvement in serum creatinine. Secondary end points included complete renal remission, systemic disease activity and damage, and safety. Overall, we did not detect a significantly different response rate between the two groups: 104 (56.2%) of 185 patients responded to MMF compared with 98 (53.0%) of 185 to IVC. Secondary end points were also similar between treatment groups. There were nine deaths in the MMF group and five in the IVC group. We did not detect significant differences between the MMF and IVC groups with regard to rates of adverse events, serious adverse events, or infections. Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.
Disciplines :
Rheumatology
Author, co-author :
Appel, Gerald B
Contreras, Gabriel
Dooley, Mary Anne
Ginzler, Ellen M
Isenberg, David
Jayne, David
Li, Lei-Shi
Mysler, Eduardo
Sanchez-Guerrero, Jorge
Solomons, Neil
Malaise, Michel ;  Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Wofsy, David
Language :
English
Title :
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
Publication date :
2009
Journal title :
Clinical Journal of the American Society of Nephrology
ISSN :
1555-9041
eISSN :
1555-905X
Publisher :
American Society of Nephrology
Volume :
20
Issue :
5
Pages :
1103-1112
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 29 June 2011

Statistics


Number of views
62 (2 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
862
Scopus citations®
without self-citations
661
OpenCitations
 
723

Bibliography


Similar publications



Contact ORBi